ALTU 139

Drug Profile

ALTU 139

Alternative Names: ALTU139

Latest Information Update: 05 Sep 2006

Price : $50

At a glance

  • Originator Altus Pharmaceuticals
  • Class
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Steatorrhoea

Most Recent Events

  • 30 Mar 2006 Discontinued - Preclinical for Steatorrhoea in USA (PO)
  • 19 Jul 2005 Preclinical trials in Steatorrhoea in USA (PO)
  • 25 May 2004 Altus Biologics is now called Altus Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top